Our Research
Three clinical studies of P2045 have been completed.
Re188-P2045 has received Orphan Drug designation for both small cell lung and pancreatic cancers, and is preparing to enter Phase 2 clinical studies.
Initial imaging (Technitium (Tc99)-P2045) and biodistribution (Tc- and Re188-P2045) studies showed that tumor uptake was rapid and substantial, and that the agent was well tolerated and rapidly cleared.
In the dose escalation study, conducted in patients who had failed other therapies, four of eight patients presenting with progressive, non-small cell lung cancer achieved stable disease at eight weeks and the median overall survival was 11.5 months, comparable to results seen with erlotinib in previously treated patients (Edelman MJ et al, J Thorac Oncol 2009, 4(12):1550-4).
Companion Diagnostics
The key to delivering personalized cancer therapy is selecting the most appropriate patients for a therapy.
Our diagnostic imaging agent is based on Technitium (Tc) 99, a widely used imaging isotope. Tc99 conjugated to P2045 targets tumors expressing high levels of SSTR2. 
Our Phase 1 clinical trial demonstrated the feasibility of using Tc99-P2045 to image patients in real time to identify the most appropriate patients (those with a high density of the SSTR2 target) for the therapeutic dose with Tozaride.
Our unique therapy is targeted to the patient’s specific molecular subtype.
Interested in knowing more? Contact us here.